The Readout

The Readout Meghana Keshavan

STAT Plus: ICER casts doubt on Sarepta’s DMD gene therapy

The Readout Elaine Chen

STAT Plus: The biotech news you need to read this morning

The Readout Elaine Chen

STAT Plus: The latest government crackdowns on biotech you need to know

The Readout Elaine Chen

STAT Plus: FDA wants to hear your thoughts on advisory committees 

The Readout Meghana Keshavan

STAT Plus: House bill aimed at Chinese biotechs is advancing 

The Readout Elaine Chen

STAT Plus: Bernie Sanders targets ‘outrageously high price’ of Ozempic

The Readout Elaine Chen

STAT Plus: A spending frenzy on obesity drugs

The Readout Elaine Chen

STAT Plus: Looking for signs of growth in Biogen’s earnings

The Readout Meghana Keshavan

STAT Plus: Novo Nordisk’s growth plan

The Readout Meghana Keshavan

STAT Plus: Amylyx’s Relvyvrio data was, as promised, disappointing

The Readout Meghana Keshavan

STAT Plus: Biohaven’s data delay degrades stock price

The Readout Meghana Keshavan

STAT Plus: A two-decade bet on Seagen pays off

The Readout Damian Garde

STAT Plus: What about the company Vertex didn’t buy?

The Readout Damian Garde

STAT Plus: Gas prices are hurting biotech

The Readout Meghana Keshavan

STAT Plus: AskBio CSO steps down, has new project in stealth mode

The Readout Damian Garde

STAT Plus: Pfizer’s plot to win the RSV vaccine race

The Readout Meghana Keshavan

STAT Plus: The latest updates on cancer research from the weekend

The Readout Meghana Keshavan

STAT Plus: Sanofi resolves most Zantac litigation

The Readout Meghana Keshavan

STAT Plus: How resurrecting extinct species might impact medicine

The Readout Meghana Keshavan

STAT Plus: New data on liquid biopsy for colorectal cancer detection still underwhelms

The Readout Meghana Keshavan

STAT Plus: Lawmakers want to add more Chinese biotechs to defense list

The Readout Meghana Keshavan

STAT Plus: Aardvark Therapeutics gearing up for $200 million IPO

The Readout Damian Garde

STAT Plus: What’s Congress going to do with WuXi?

The Readout Meghana Keshavan

STAT Plus: How GLP-1’s moved from research labs to national TV

The Readout Damian Garde

STAT Plus: Brazil’s plan for low-cost CAR-Ts

The Readout Damian Garde

STAT Plus: Merck’s next big thing is (probably) on the way

The Readout Meghana Keshavan

How will the Supreme Court’s mifepristone decision impact biopharma?

The Readout Meghana Keshavan

STAT Plus: EU adviser says Illumina merger was not problematic

The Readout Damian Garde

STAT Plus: BioNTech is having its Pfizer moment